Stock EYPT EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
16.47 USD -6.26% Intraday chart for EyePoint Pharmaceuticals, Inc. -21.35% -28.73%
Apr. 02 EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board CI
Mar. 18 EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index CI

Evolution of the average Target Price on EyePoint Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1bb41e.RVjkXW1KpnvVKYLuzPb_YZYxFQez3uFCUihmum7zvhU.C2iFDB4-kzXnHvG7lp6dMNtuIH3F7IUPMRBLwFaH9kJ0KJZqAH38E7FYyw~6730064feb25b57f73a5fd11cef86a7c

Analyst Recommendations on EyePoint Pharmaceuticals, Inc.

Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating MT
JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target MT
Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target MT
Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating MT
Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20 MT
JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $27 From $25, Keeps Buy Rating MT
Chardan Raises Price Target on EyePoint Pharmaceuticals to $22 From $21, Keeps Buy Rating MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $52 From $60, Maintains Buy Rating MT
HC Wainwright Lifts Price Target on EyePoint Pharmaceuticals to $25 From $24, Reiterates Buy Rating MT
Chardan Capital Initiates EyePoint Pharmaceuticals at Buy with $21 Price Target MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $75 From $22, Maintains Buy Rating MT
Cowen Adjusts Price Target on EyePoint Pharmaceuticals to $35 From $25, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $24 From $15, Keeps Buy Rating MT
EYEPOINT PHARMACEUTICALS : HC Wainwright Adjusts EyePoint Pharmaceuticals' Price Target to $15 From $16, Maintains Buy Rating MT
EYEPOINT PHARMACEUTICALS : Cowen Starts EyePoint Pharmaceuticals at Outperform with $25 Price Target MT
EYEPOINT PHARMACEUTICALS : Cantor Fitzgerald Starts EyePoint Pharmaceuticals at Overweight With $22 Price Target MT
EYEPOINT PHARMACEUTICALS : B. Riley Adjusts EyePoint Pharmaceuticals' Price Target to $8.50 from $5, Keeps Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.47 USD
Average target price
43.89 USD
Spread / Average Target
+166.48%
High Price Target
68 USD
Spread / Highest target
+312.87%
Low Price Target
33 USD
Spread / Lowest Target
+100.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering EyePoint Pharmaceuticals, Inc.

Mizuho Securities
JPMorgan Chase
Capital One Securities
HC Wainwright
JonesTrading Institutional Services
Chardan Research
Guggenheim
Cowen
Cantor Fitzgerald
B. Riley

Ratings for EyePoint Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. Consensus EyePoint Pharmaceuticals, Inc.